JAMA Oncology (journal)
-
April 28, 2022
Studies combine genetic testing, electronic health records to find undiagnosed diseases
Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations. -
December 9, 2021
Prostate cancer treatment regret
Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity. -
April 15, 2021
Method proposed to correct misinterpretations of long-term survival rates for immunotherapies
Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology. -
March 25, 2021
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology. -
March 18, 2021
Vanderbilt research played key role in new lung screen guidelines
The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20. -
March 9, 2021
Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening
A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening. -
July 23, 2020
Criteria for lung cancer screens may be expanded
The U.S. Preventive Services Task Force (USPSTF) is recommending two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.